These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30076385)

  • 21. Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.
    Miyabe Y; Lian J; Miyabe C; Luster AD
    Nat Rev Rheumatol; 2019 Dec; 15(12):731-746. PubMed ID: 31705045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S100A8/A9, a potent serum and molecular imaging biomarker for synovial inflammation and joint destruction in seronegative experimental arthritis.
    Geven EJ; van den Bosch MH; Di Ceglie I; Ascone G; Abdollahi-Roodsaz S; Sloetjes AW; Hermann S; Schäfers M; van de Loo FA; van der Kraan PM; Koenders MI; Foell D; Roth J; Vogl T; van Lent PL
    Arthritis Res Ther; 2016 Oct; 18(1):247. PubMed ID: 27776554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases.
    Baillet A; Trocmé C; Berthier S; Arlotto M; Grange L; Chenau J; Quétant S; Sève M; Berger F; Juvin R; Morel F; Gaudin P
    Rheumatology (Oxford); 2010 Apr; 49(4):671-82. PubMed ID: 20100792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis.
    Foell D; Wittkowski H; Roth J
    Nat Clin Pract Rheumatol; 2007 Jul; 3(7):382-90. PubMed ID: 17599072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nerve growth factor in rheumatic diseases.
    Seidel MF; Herguijuela M; Forkert R; Otten U
    Semin Arthritis Rheum; 2010 Oct; 40(2):109-26. PubMed ID: 19481238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.
    Andrés Cerezo L; Šumová B; Prajzlerová K; Veigl D; Damgaard D; Nielsen CH; Pavelka K; Vencovský J; Šenolt L
    Arthritis Res Ther; 2017 Apr; 19(1):79. PubMed ID: 28446208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomics in rheumatic diseases: desperately seeking biomarkers.
    Guma M; Tiziani S; Firestein GS
    Nat Rev Rheumatol; 2016 May; 12(5):269-81. PubMed ID: 26935283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology.
    Medkova A; Srovnal J; Potomkova J; Volejnikova J; Mihal V
    World J Pediatr; 2018 Aug; 14(4):315-321. PubMed ID: 29858979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S100A8/A9 and S100A9 reduce acute lung injury.
    Hiroshima Y; Hsu K; Tedla N; Wong SW; Chow S; Kawaguchi N; Geczy CL
    Immunol Cell Biol; 2017 May; 95(5):461-472. PubMed ID: 28074060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serglycin expression in CD2+ and CD14+ cells from patients with various rheumatic diseases.
    Omtvedt LA; Kolset SO; Thoen J; Førre Y; Gill MR
    Scand J Rheumatol; 2001; 30(3):164-6. PubMed ID: 11469527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of biochemical markers of joint tissue remodelling to predict progression and treatment efficacy in inflammatory rheumatic diseases.
    Garnero P; Landewé R; Chapurlat RD
    Rheumatology (Oxford); 2020 Jun; 59(6):1207-1217. PubMed ID: 32011708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial progenitor cells and rheumatic disease modifying therapy.
    Lo Gullo A; Aragona CO; Scuruchi M; Versace AG; Saitta A; Imbalzano E; Loddo S; Campo GM; Mandraffino G
    Vascul Pharmacol; 2018 Sep; 108():8-14. PubMed ID: 29842927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs.
    Schub D; Assmann G; Sester U; Sester M; Schmidt T
    Arthritis Res Ther; 2018 Nov; 20(1):252. PubMed ID: 30413189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of calcium-binding proteins S100A8, S100A9 and S100A12 in otitis media.
    Hong W; Khampang P; Samuels TL; Kerschner JE; Yan K; Simpson P
    Int J Pediatr Otorhinolaryngol; 2017 Oct; 101():30-36. PubMed ID: 28964306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.
    Hu C; Lu L; Wan JP; Wen C
    Curr Med Chem; 2017; 24(20):2241-2249. PubMed ID: 28302011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases.
    Fechtner S; Fox DA; Ahmed S
    Rheumatology (Oxford); 2017 Jul; 56(7):1060-1068. PubMed ID: 27550296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitrite correlates with 3-nitrotyrosine but not with the F(2)-isoprostane 15(S)-8-iso-PGF(2alpha) in urine of rheumatic patients.
    Pham VV; Stichtenoth DO; Tsikas D
    Nitric Oxide; 2009; 21(3-4):210-5. PubMed ID: 19737619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S100 family proteins in inflammation and beyond.
    Sreejit G; Flynn MC; Patil M; Krishnamurthy P; Murphy AJ; Nagareddy PR
    Adv Clin Chem; 2020; 98():173-231. PubMed ID: 32564786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel immunological targets in rheumatic diseases: clues from current therapies.
    D'Acquisto F; Rattazzi L; Piras G; Galuppo ML
    Drug Discov Today; 2014 Aug; 19(8):1155-60. PubMed ID: 24984284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.